Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery

Launched by YONGTAO SUN · Apr 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how different levels of frailty in elderly patients affect the dosage of a pain medication called nalbuphine when used after laparoscopic gastrointestinal (GI) surgery. The goal is to find the right amount of nalbuphine that, when combined with another medication, provides effective pain relief while minimizing complications. By understanding how frailty impacts pain management, the researchers hope to improve recovery for older adults after surgery.

To be eligible for this study, participants must be at least 65 years old, plan to have elective GI surgery with a hospital stay of three days or more, and have a body mass index (BMI) between 18.5 and 30. The study will not include patients with severe health issues, recent treatments like chemotherapy, or those who have participated in other clinical trials recently. If eligible, participants can expect to receive personalized pain management after their surgery while helping researchers gather important information that could enhance care for frail patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who plan to undergo elective gastrointestinal surgery and are expected to stay in hospital for ≥3 days after surgery \[except abdominal perineal combined with radical resection of rectal cancer (MILES)\];
• • 2. ASA grade I-Ⅳ;
• • 3. Age ≥65 years (2);
• • 4. 18.5 kg/m²≤BMI\<30 kg/m²;
• • 5. Sign the informed consent form.
• Exclusion Criteria:
• • 1. Severe cardiopulmonary, liver, kidney and coagulation dysfunction
• • 2. Chemotherapy and radiotherapy were administered 1 month before surgery, and sedatives, antiemetic or antipruritic drugs were administered 24 hours before surgery
• • 3. History of drug abuse, chronic pain, mental illness, or allergy to the drugs used in this study
• • 4. Plan postoperative intubation or transfer to ICU;
• • 5. Participated in other clinical studies within the past 3 months.